Who are subjected to Octreotide?
• For the relief of symptoms associated with gastroenteropancreatic endocrine tumors including caracinoid tumors with features of characinoid syndrome, VIPomas and glucagonomas. You must know that Octreotide is not an antitumor therapy and is not curative in these patients. • for symptomatic control and reduction of growth hormone (GH) and somatomedin C plasma levels in patients with acromegaly: • In short-term treatment prior to pituitary surgery or • In long-term treatment in those who are inadequately controlled by pituitary surgery, dopamine agonist treatment, radiotherapy or in the interim period until radiotherapy becomes fully effective.’ Octreotide is indicated for acromegalic patients for whom surgery is inappropriate. Carcinoid Syndrome Carcinoid tumors are the most common neuroendocrine tumours of the gastrointestinal tract with an estimated incidence of 2.1/100,000. The 5 year life expectancy for untreated disease is only 8-21%. The therapeutic options available to manage c
